Voyager Therapeutics Inc VYGR

Healthcare Biotechnology

Voyager Therapeutics, Inc. is a biotechnology company focused on advancing neurogenetic medicines. The Company’s pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of its programs are derived from its TRACER AAV capsid discovery platform, which is used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs, all of which are in preclinical development, include Anti-Tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy Program, Tau Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program, and others. VY-TAU01 is for the treatment of Alzheimer’s disease. SOD1 Silencing Gene Therapy Program is for the treatment of ALS.

NDAQ:VYGR - Post by User

Voyager Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

(69)
•••

Post by Iseneschalon Nov 02, 2021 12:49pm

79 Views

Post# 34077932

VYGR ...... don't worry about the man behind the curtain!

It was just Mr. Maggot trying to shake everyone out of this ....slow bleed after ER news

What did you expect?

Still long and not leaving .

Cheers !

<< Previous

Bullboard Posts

Next >>

Cizzle Brands, Changing Consumer Habits in Consumables